6.925

3.28% -0.235

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $6.925, with a volume of 1.21M. It is down -3.28% in the last 24 hours and down -13.22% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Previous Close:

$7.16

Open:

$7.14

24h Volume:

1.21M

Relative Volume:

0.80

Market Cap:

$457.14M

Revenue:

$170.44M

Net Income/Loss:

$-193.88M

P/E Ratio:

-1.8446

EPS:

-3.7541

Net Cash Flow:

$-126.38M

1W Performance:

-14.19%

1M Performance:

-13.22%

6M Performance:

-24.65%

1Y Performance:

-43.88%

1-Day Range:

$6.875

$7.18

1-Week Range:

$6.80

$8.29

52-Week Range:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

371

Twitter

@REGENXBIO

Next Earnings Date

2026-11-05

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	6.925	457.14M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-05-26	Initiated	Mizuho	Outperform
Aug-07-26	Downgrade	Barclays	Overweight → Equal Weight
Jan-28-26	Resumed	Barclays	Overweight
Feb-11-25	Downgrade	Goldman	Buy → Neutral
Feb-07-25	Resumed	Raymond James	Outperform
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

Oct 13, 2026

JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX). - Stock Titan

Oct 13, 2026

Oct 12, 2026

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - www.marketscreener.com

Oct 12, 2026

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - PR Newswire

Oct 12, 2026

Oct 09, 2026

Gene Therapy Patent Suit Against Sarepta Comes To Close - Law360

Oct 09, 2026

Oct 08, 2026

Regenxbio, Penn End Revived Sarepta Gene-Therapy Patent Fight - Bloomberg Law News

Oct 08, 2026

Oct 05, 2026

Exclusive BAC Article: REGENXBIO; BLA Submisison RGX-202 DMD Q3 2026, Topline Data Ph3 ABBV-RGX-314 Wet-AMD Q4 2026, And Catalysts (NASDAQ:RGNX) - Seeking Alpha

Oct 05, 2026

Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin - GuruFocus

Oct 05, 2026

RGNX Initiates Coverage On Mizuho -- Rating Set to Outperform - GuruFocus

Oct 05, 2026

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call - Yahoo Finance

Oct 05, 2026

Full Transcript: Regenxbio Q2 2026 Earnings Call - Benzinga

Oct 05, 2026

Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com South Africa

Oct 05, 2026

Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com Nigeria

Oct 05, 2026

Mizuho initiates Regenxbio stock coverage with outperform rating - Investing.com

Oct 05, 2026

Sep 29, 2026

ETFs Investing in REGENXBIO, Inc. Stocks - TradingView

Sep 29, 2026

Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0 - TradingView

Sep 29, 2026

Sep 28, 2026

H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data - Investing.com

Sep 28, 2026

Sep 25, 2026

REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine

Sep 25, 2026